Quantifying Specific Nanoparticle Phenotypes in Complex Biological Fluids by Fluorescence Microfluidic Resistive Pulse Sensing.

项目总结 基于细胞外小泡(EV)的治疗和载体介导的基因治疗具有巨大的前景 疾病治疗学。两者都由直径30 nm至300 nm的纳米颗粒组成，这些颗粒是在 复杂和异质的生物系统。将这些材料转化为有效的和商业的 可行的产品需要对感兴趣的颗粒的浓度和大小进行准确测量(例如， 病毒或电动汽车)，以及研究、开发和生产所有阶段的任何杂质。 然而，目前还没有准确的工具来量化这些基本参数。最可用的 方法不能在相关的尺寸范围内以及在诸如 这些应用程序所需的。其他方法可能需要几天的时间(例如生物滴度)，并且几乎没有提供任何结果 有关颗粒杂质的信息。这些技术充其量只会造成瓶颈，因为它们需要繁琐的程序 和昂贵的测量前净化；在最坏的情况下，他们的测量被误解-重要的是 对病人安全的影响。因此，存在着对提供快速和 精确测量复杂生物混合物中特定颗粒的大小和浓度。 Spetradyne已经将微流控电阻脉冲传感(MRPS)商业化，这是一种电子技术， 独一无二地适用于分析复杂的异质样品。MRPS在行业中迅速采用，并 学术界对EVS和病毒的量化。而MRPS精确地测量了复合体中的所有颗粒 对于样品，它目前无法将感兴趣的颗粒与样品中其他类似大小的颗粒区分开来。 Spectradyne将开发Fluor-MRPS，这是一项强大的新技术，它增加了单粒子的特异性 荧光测量到MRPS平台。这项新技术将测量大小， 溶液中单个颗粒的浓度和表型具有前所未有的准确性，以及 大大减少生产生物衍生材料的时间和成本，如病毒和EV- 以治疗学为基础。 为了实现这些目标，将在项目的第一和第二阶段实现五个具体目标。在第一阶段的目标中，一个 将生产出能够同时进行单次MRPS和荧光分析的样机 粒子。将对灵敏度和吞吐量进行基准测试。在第二阶段的目标中，原型将进行优化 对于小颗粒检测，全面评估检测的特异性、敏感性和极限，并部署 用于在真实世界中与最终用户进行Beta测试。 这项工作的完成将产生一个易于使用的台式仪器，能够快速和准确的尺寸和 特殊标记纳米粒子表型和络合物中杂质的浓度测量 生物媒体。福陆-MRPS将提供显著的效率和强大的新功能 基因治疗载体和EV治疗药物的开发和生产。

PROJECT SUMMARY Extracellular vesicle (EV)-based therapies and vector-mediated gene therapies hold enormous promise as disease therapeutics. Both comprise nanoscale particles 30nm to 300 nm in diameter that are produced in complex and heterogeneous biological systems. To translate these materials into effective and commercially viable products requires accurate measurements of the concentration and size of the particles of interest (e.g., virus or EVs), and of any impurities at all stages of research, development and production. However, accurate tools for quantifying these basic parameters are not currently available. Most available methods are incapable of accurate measurements in the relevant size range and in such complex media as required for these applications. Other methods can take days (e.g., biological titer) and provide little or no information about particle impurities. At best these techniques create a bottleneck by requiring cumbersome and costly pre-measurement purification; at worst their measurements are misinterpreted—with important implications for patient safety. A critical unmet need therefore exists for technology that delivers fast and accurate size and concentration measurements of specific particles in complex biological mixtures. Spectradyne has commercialized Microfluidic Resistive Pulse Sensing (MRPS), an electrical technique that is uniquely suited to analyzing complex heterogeneous samples. MRPS is seeing rapid adoption in industry and academia for quantification of EVs and virus. While MRPS accurately measures all particles in a complex sample, it cannot currently distinguish the particles of interest from other similarly-sized particles in the sample. Spectradyne will develop Fluor-MRPS, a powerful new technology that adds the specificity of single-particle fluorescence measurements to the MRPS platform. This new technology will measure the size, concentration, and phenotype of single particles in solution with unprecedented accuracy, and dramatically reduce the time and cost of producing biologically derived materials such as virus- and EV- based therapeutics. To accomplish these goals, five specific aims will be met in Phase I and II of the project. In the Phase I Aims, a prototype instrument will be produced that is capable of simultaneous MRPS and fluorescence analysis of single particles. Sensitivity and throughput will be benchmarked. In the Phase II Aims, the prototype will be optimized for small particle detection, thoroughly evaluated for specificity, sensitivity, and limit of detection, and deployed for beta testing with end users in the real world. Completion of this work will yield an easy-to-use bench top instrument capable of rapid and accurate size and concentration measurements of both specifically labeled nanoparticle phenotypes and impurities in complex biological media. Fluor-MRPS will deliver significant efficiencies and powerful new capabilities in the development and production of gene therapy vectors and EV-based therapeutics.